ReForm Biologics and MilliporeSigma sign licensing agreement for excipient development

ReForm Biologics and MilliporeSigma (the Life Science business of Merck KGaA) announced a global license agreement to commercialize ReForm's proprietary excipients for biotherapeutic formulations. MilliporeSigma will fund R&D and handle commercialization and GMP manufacturing.

“MilliporeSigma is a global leader in providing pharmaceutical excipients for biologic formulation.”pharmaceuticaldaily.com

• 1 source
• pharmaceuticaldaily.comReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization – pharmaceutical dailyBusinessWireFeb 10, 2020

Summarized from public sources; check the original articles before acting on it.